Hospital

Insulin-aspart-szjj (Merilog) is the first rapid-acting insulin biosimilar product approved by the FDA.

OPN-6602 is an oral EP300/CBP bromodomain inhibitor that yielded 100% tumor regression as a combination therapy in mouse models.

The combination of the antibody-drug conjugate and PD-1/L1 inhibitor yielded an improved progression-free survival in locally advanced or metastatic urothelial carcinoma.

The data were presented at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco, California.

The cancer cells developed their own electrical network similar to neural behavior seen in the brain.

Treatment with 2.4 mg of semaglutide did not increase the risk of developing suicidal ideation or behavior compared with placebo.

After gradually consuming increased doses of peanut butter, children who could initially tolerate about half a peanut could consume 3 tablespoons without an allergic reaction.

The expanding role of real-world evidence in regulatory and health technology assessment (HTA) decision-making highlights its growing acceptance for supplementing clinical trial data, addressing evidence gaps, and informing treatment value, despite challenges in data quality, accessibility, and regulatory compliance.

Andrew Lin, PharmD, BCOP, discusses his pharmacist-led study examining the association between early tacrolimus levels and outcomes post-allogeneic hematopoietic cell transplantation.

Talazoparib in combination with enzalutamide yielded significant improvements in radiographic progression-free survival and overall survival.

This surgery can be significant in reducing the long-term risk of adverse outcomes and decompensation in cirrhosis related to metabolic dysfunction-associated steatohepatitis (MASH).

Diabetes management through insulin could play a significant role in preventing antibiotic resistance.

Up to 61% of all non-small cell lung cancer (NSCLC) cases harbor EGFR mutations.

Avacincaptad pegol intravitreal solution is a prescription eye injection used to treat geographic atrophy.

Risdiplam is the only approved non-invasive disease-modifying SMA treatment.

Duloxetine offers treatment for various neuro-psychiatric and pain disorders in patients who have difficulty swallowing.

Reductions in cerebellar volume were associated with cognitive deficits and lower kidney function in those with CKD.

Cytopenic myelofibrosis is characterized by poorer prognosis and more severe anemia and thrombocytopenia compared with proliferative myelofibrosis.

Presence of leptomeningeal disease is associated with poorer treatment outcomes and quality of life for patients with breast cancer.

Emerging data indicate that COVID-19 is also characterized by inflammation present in the heart and other organs

Thalassemia, a chronic blood condition that reduces hemoglobin levels, requires a hands-on approach from pharmacists in patient monitoring and diagnosis.

Circulating lactate is increased in patients with myelofibrosis and corresponds with the remodeling of lactate export channel monocarboxylate transporter 4, suggesting a link with fibrosis establishment.

If approved, HLX11 could offer a more cost-effective alternative to pertuzumab for the treatment of human epidermal growth factor receptor 2-positive breast cancer.

BR55, an injection of perfluorobutane/nitrogen lipopeptide-coated microbubbles, could aid in the detection of angiogenesis and allow for earlier diagnosis in patients with Crohn disease.

The therapeutic vaccine could provide patients with a non-surgical alternative to traditional treatment approaches.

These findings can lay the foundation for the development of machine learning models in chronic kidney disease (CKD) and kidney failure.

Age, body mass index, and male sex are also associated with the development of diabetes.

The quadruple treatment was active and safe as initial therapy for older patients with transplant-ineligible multiple myeloma.